(Q39775481)

14 September 2017

OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways (English)

1 reference

14 September 2017

1 reference

Wen-Yi Wang

1

1 reference

14 September 2017

Jie Li

2

1 reference

14 September 2017

Ding Yang

3

1 reference

14 September 2017

Wei Xu

4

1 reference

14 September 2017

Ruo-peng Zha

5

1 reference

14 September 2017

Yi-ping Wang

6

1 reference

14 September 2017

12 November 2009

1 reference

14 September 2017

Cardiovascular Research

1 reference

14 September 2017

85

1 reference

14 September 2017

4

1 reference

14 September 2017

845-852

1 reference

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target

14 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Low density lipoprotein oxidation and its pathobiological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Platelet-activating factor acetylhydrolases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

HDL and the inflammatory response induced by LDL-derived oxidized phospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Expression and purification of lipoprotein-associated phospholipase A(2), a key enzyme involved in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Oxidized phospholipids reduce ventilator-induced vascular leak and inflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Anti-inflammatory properties of lipid oxidation products

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Evidence for a role of phospholipid oxidation products in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Oxidized phospholipids as modulators of inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

PI3K p110beta positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1 beta in RAW264 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP367

21 January 2018

Identifiers

DOI

10.1093/CVR/CVP367

1 reference

14 September 2017

1 reference